Gilead Sciences GILD Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AmBisome | $508M-4.0% | $509M-4.7% | $500M-6.7% | $507M-2.7% | $529M+1.5% | |
| Biktarvy | $14.55B+6.7% | $14.33B+6.8% | $14.14B+10.8% | $13.93B+12.6% | $13.63B+12.5% | |
| Descovy | $2.98B+31.0% | $2.76B+30.5% | $2.56B+27.4% | $2.44B+26.4% | $2.27B+15.8% | |
| Genvoya | $1.4B-18.9% | $1.5B-15.0% | $1.59B-12.2% | $1.66B-10.8% | $1.72B-12.2% | |
| Odefsey | $1.11B-12.1% | $1.17B-9.4% | $1.19B-7.6% | $1.24B-5.0% | $1.26B-6.3% | |
| Other HIV | $482M+18.1% | $500M+15.2% | $422M+5.0% | $410M+3.5% | $408M-0.7% | |
| Other Liver Disease | $827M+72.3% | $834M+79.0% | $683M+58.1% | $568M+35.9% | $480M+20.0% | |
| Other | $278M-19.7% | $290M-18.5% | $279M-24.8% | $289M-27.9% | $346M-4.7% | |
| Royalty, contract and other revenues | $487M+208% | $527M+269% | $538M+249% | $144M-20.0% | $158M-9.2% | |
| Sofosbuvir/Velpatasvir | $1.21B-21.3% | $1.27B-20.2% | $1.33B-19.3% | $1.4B-14.2% | $1.54B-1.3% | |
| Symtuza - Revenue share | $519M-8.1% | $495M-16.4% | $506M-12.8% | $521M-9.2% | $565M+5.1% | |
| Tecartus | $340M-10.8% | $343M-14.9% | $351M-12.9% | $366M-8.7% | $381M-0.3% | |
| Trodelvy | $1.51B+15.9% | $1.4B+6.2% | $1.37B+8.7% | $1.34B+11.0% | $1.3B+12.9% | |
| Veklury | $753M-51.3% | $911M-49.4% | $1.04B-52.4% | $1.45B-31.6% | $1.55B-28.6% | |
| Vemlidy | $1.06B+7.0% | $1.07B+11.6% | $1.04B+13.8% | $996M+9.1% | $987M+11.0% | |
| Yescarta | $1.44B-8.5% | $1.5B-4.7% | $1.52B-2.1% | $1.56B+0.1% | $1.58B+3.8% | |
| Total revenues by Geography | ||||||
| Europe | $5.12B+12.4% | $5.06B+9.3% | $5B+8.2% | $4.62B+2.6% | $4.56B+3.8% | |
| Rest of World | $3.48B-2.0% | $3.5B-0.7% | $3.52B+1.4% | $3.51B-0.5% | $3.55B+3.1% | |
| U.S. | $21.13B+2.5% | $20.88B+1.4% | $20.57B+1.8% | $20.74B+4.9% | $20.63B+5.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gilead Sciences break its business down?
- Gilead Sciences (GILD) reports total revenues by product across 18 parts — AmBisome, Biktarvy, Descovy, Genvoya and Livdelzi. Each is extracted from the segment footnotes and tracked over time.
- Where does Gilead Sciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gilead Sciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
